by Sean Poulter
DailyMail.co.uk 

Russia has suspended the import and use of an American GM corn following a study suggesting a link to breast cancer and organ damage.

Separately, the European Food Safety Authority(EFSA), has ordered its own review in to the research, which was conducted at a French university.

The decision by Russia could be followed by other nations in what would be a severe blow to the take-up of the controversial technology.

Historically, biotech companies have proved the safety of GM crops based on trials involving feeding rats for a period of 90 days.

However, experts at the University of Caen conducted an experiment running for the full lives of rats – two years.

The findings, which were peer reviewed by independent experts before being published in a respected scientific journal, found raised levels of breast cancer, liver and kidney damage.

Read the full article here: http://www.dailymail.co.uk/news/article-2208452/Russia-suspends-import-use-American-GM-corn-study-revealed-cancer-risk.html

See Also: First-Ever Lifetime Feeding Study Finds Genetically Engineered Corn Causes Massive Tumors, Organ Damage, and Early Death

We Lost the War on Cancer – Review of Alternative Cancer Therapies

eBook
Retail : $9⁹⁹
Now : $5⁹⁹

We have lost the war on cancer. At the beginning of the last century, one person in twenty would get cancer. In the 1940s it was one out of every sixteen people. In the 1970s it was one person out of ten. Today one person out of three gets cancer in the course of their life.

The cancer industry is probably the most prosperous business in the United States. In 2014, there will be an estimated 1,665,540 new cancer cases diagnosed and 585,720 cancer deaths in the US. $6 billion of tax-payer funds are cycled through various federal agencies for cancer research, such as the National Cancer Institute (NCI). The NCI states that the medical costs of cancer care are $125 billion, with a projected 39 percent increase to $173 billion by 2020.

The simple fact is that the cancer industry employs too many people and produces too much income to allow a cure to be found. All of the current research on cancer drugs is based on the premise that the cancer market will grow, not shrink.

John Thomas explains to us why the current cancer industry prospers while treating cancer, but cannot afford to cure it in Part I. In Part II, he surveys the various alternative cancer therapies that have been proven effective, but that are not approved by the FDA.